212 related articles for article (PubMed ID: 22009610)
21. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
Dzau VJ
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):74-80. PubMed ID: 3037893
[TBL] [Abstract][Full Text] [Related]
22. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
[TBL] [Abstract][Full Text] [Related]
23. Pathophysiology of fluid retention in heart failure.
Chaney E; Shaw A
Contrib Nephrol; 2010; 164():46-53. PubMed ID: 20427993
[TBL] [Abstract][Full Text] [Related]
24. Edematous disorders: pathophysiology of renal sodium and water retention and treatment with diuretics.
Abraham WT; Schrier RW
Curr Opin Nephrol Hypertens; 1993 Sep; 2(5):798-805. PubMed ID: 7922221
[TBL] [Abstract][Full Text] [Related]
25. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
[TBL] [Abstract][Full Text] [Related]
26. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
27. Breakdown of blood pressure and body fluid homeostasis in heart transplant recipients.
Braith RW; Mills RM; Wilcox CS; Davis GL; Wood CE
J Am Coll Cardiol; 1996 Feb; 27(2):375-83. PubMed ID: 8557909
[TBL] [Abstract][Full Text] [Related]
28. Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure.
Veeraveedu PT; Watanabe K; Ma M; Palaniyandi SS; Yamaguchi K; Kodama M; Aizawa Y
Biochem Pharmacol; 2008 Mar; 75(6):1322-30. PubMed ID: 18179782
[TBL] [Abstract][Full Text] [Related]
29. Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics.
Costello-Boerrigter LC; Boerrigter G; Burnett JC
Med Clin North Am; 2003 Mar; 87(2):475-91. PubMed ID: 12693735
[TBL] [Abstract][Full Text] [Related]
30. Renin secretion and total body sodium: pathways of integrative control.
Bie P; Damkjaer M
Clin Exp Pharmacol Physiol; 2010 Feb; 37(2):e34-42. PubMed ID: 19843096
[TBL] [Abstract][Full Text] [Related]
31. Haemodynamic impact of diuretic therapy in chronic heart failure.
Silke B
Cardiology; 1994; 84 Suppl 2():115-23. PubMed ID: 7954533
[TBL] [Abstract][Full Text] [Related]
32. Water and sodium regulation in heart failure.
Bae EH; Ma SK
Electrolyte Blood Press; 2009 Dec; 7(2):38-41. PubMed ID: 21468184
[TBL] [Abstract][Full Text] [Related]
33. ANP-induced signaling cascade and its implications in renal pathophysiology.
Theilig F; Wu Q
Am J Physiol Renal Physiol; 2015 May; 308(10):F1047-55. PubMed ID: 25651559
[TBL] [Abstract][Full Text] [Related]
34. Sodium and water retention in heart failure: pathogenesis and treatment.
Martin PY; Schrier RW
Kidney Int Suppl; 1997 Jun; 59():S57-61. PubMed ID: 9185106
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the understanding of water metabolism in heart failure.
Schrier RW; Martin PY
Adv Exp Med Biol; 1998; 449():415-26. PubMed ID: 10026833
[TBL] [Abstract][Full Text] [Related]
36. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery.
Anand IS; Chandrashekhar Y; Ferrari R; Sarma R; Guleria R; Jindal SK; Wahi PL; Poole-Wilson PA; Harris P
Circulation; 1992 Jul; 86(1):12-21. PubMed ID: 1617764
[TBL] [Abstract][Full Text] [Related]
37. Edema formation in congestive heart failure and the underlying mechanisms.
Abassi Z; Khoury EE; Karram T; Aronson D
Front Cardiovasc Med; 2022; 9():933215. PubMed ID: 36237903
[TBL] [Abstract][Full Text] [Related]
38. Atrial natriuretic hormone, the renin-aldosterone axis, and blood pressure-electrolyte homeostasis.
Laragh JH
N Engl J Med; 1985 Nov; 313(21):1330-40. PubMed ID: 2932646
[TBL] [Abstract][Full Text] [Related]
39. Control of blood and extracellular volume.
Cowley AW; Roman RJ
Baillieres Clin Endocrinol Metab; 1989 Aug; 3(2):331-69. PubMed ID: 2698141
[TBL] [Abstract][Full Text] [Related]
40. Effects of chronic rosiglitazone treatment on renal handling of salt and water in rats with volume-overload congestive heart failure.
Goltsman I; Wang X; Lavallie ER; Diblasio-Smith EA; Ovcharenko E; Hoffman A; Abassi Z; Feuerstein GZ; Winaver J
Circ Heart Fail; 2011 May; 4(3):345-54. PubMed ID: 21398416
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
